EVÄVAARA-DESIGN
Remote working has raised a number of challenges that have been taken up by Finnish pioneering designer of functional furniture, Evävaara Design. Evävaara is launching two completely new workstation designs to fit any home: the larger, mobile sshhh 3 and the smaller sshhh 7 . The workstations support the wellbeing of employees with good ergonomic and acoustic design.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210511005612/en/
Antti Evävaara, founder and chief designer of Evävaara Design, has almost twenty years’ experience in designing and producing functional furniture, with solid expertise in good acoustics and user comfort, which provide the basis for their workstation design.
“In today’s world we are constantly surrounded by irritants and noise that can make it hard to focus on something. Our products aim to create a quiet, personal space that allows you to focus”, says Evävaara .
The furniture-shaped workstations designed by Evävaara are a response to the challenges posed by the increase in remote working. According to remote work and virtual leadership expert Ulla Vikman of Timanttia Consulting, those who do a great deal of remote work, often experience interruptions and are sometimes challenged by a blurred line between work and free time.
“Someone who does a great deal of remote work would be distracted if the necessary tools, such as displays and paperwork, are constantly on all over their home. By intruding your thoughts constantly, these things tend to increase stress levels and focusing becomes more difficult”, says Vikman .
The design of Evävaara workstations is focused on a number of details that support concentration and ergonomics. The wood and felt of the workstation muffles both external and internal noise and improves the acoustics of the whole room. Standard equipment for the workstation includes
- Power sockets and cords
- USB port
- LED lights
- Storage pockets for paperwork and other materials
The larger sshhh3 can be purchased with an additional, adjustable chair. After work, the workstation doors are simply closed and the workstation becomes a mobile cabinet. A neutral colour scheme makes the unit blend seamlessly in any home environment.
In order to boost the efficiency of your working day, Evävaara Design workstations are easy to deploy. The workstation is delivered assembled and ready to use. Evävaara Design workstations are available direct from the designer.
Today the products of Evävaara Design are in use all over Europe wherever a calm space is required, for instance in open plan offices and libraries. They have also garnered some international interest since Vincent Gregoire, Nelly Rodi’s creative director and a celebrity in the business, included Evävaara products in a video showcasing new trends at the Maison & Objet fair in February.
More information: https://www.evavaaradesign.com/etatyopisteet/
Evavaara Design is a Finnish pioneer in functional furniture design in Europe – creating quiet corners for every environment.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210511005612/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release
- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and
Leading Global Scientists Gather at Tengchong Scientists Forum to Explore Innovative Pathways in Frontier Technologies6.12.2025 12:31:00 CET | Press release
The 2025 Tengchong Scientists Forum opened on Saturday in southwest China’s Yunnan Province, convening leading scientists and academic figures to examine innovation across frontier fields including artificial intelligence, biodiversity and quantum technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205499197/en/ Opening ceremony of Tengchong Scientists Forum on 6th December, 2025 Notable participants include Nobel Physics laureate Konstantin Novoselov, Fields Medalist Efim Zelmanov and Turing Award winner Andrew Chi-Chih Yao, who join 127 academicians, 77 university presidents from China and abroad, over 400 scholars and more than 600 entrepreneurs and financiers. The gathering aims to deepen collaboration between cutting-edge research and industrial development. Under the theme “Science · AI changing the World,” the forum features ten sub-forums, academic sessions and thematic events supporting major cooperation p
Lattice Wins 2025 Global Semiconductor Alliance Award6.12.2025 00:49:00 CET | Press release
‒ Named Most Respected Public Semiconductor Company Achieving $100 Million to $500 Million in Annual Sales ‒ Lattice Semiconductor (NASDAQ: LSCC), the low power programmable leader, today announced that it was selected as ‘Most Respected Public Semiconductor Company’ at the 2025 Global Semiconductor Alliance (GSA) Awards. The GSA awards recognize companies that have demonstrated excellence through their success, vision, strategy, and future opportunities in the industry as determined by votes from GSA members. “We are honored to be recognized by the Global Semiconductor Alliance and our peers as one of 2025’s most respected public semiconductor companies. This recognition reflects the dedication of the Lattice team and the trust of our customers, partners, suppliers, and investors. Looking ahead, we remain laser-focused on driving innovation and strengthening our role as the trusted low power programmable leader for semiconductor and system solutions,” said Ford Tamer, Chief Executive
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom